Arvinas Announces Upcoming Bavdegalutamide Poster

NEW HAVEN, Conn., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

Related Keywords

Spain ,Madrid ,Daniel Petrylak ,Jeff Boyle ,Kirsten Owens ,Arvinas Inc ,Nasdaq ,Exchange Commission ,European Society For Medical Oncology ,Medical Oncology ,Discovery Engine ,Private Securities Litigation Reform Act ,Arvina Annual Report ,Nasdaq Arvn ,Rvinas Inc ,Breast Cancer ,Prostate Cancer ,Protac ,Protein Degradation ,Targeted Protein Degradation ,Immuno Oncology ,Ncology ,